MÁLAGA, 11 (EUROPA PERS)
Investigators from the University of Málaga (UMA) have discovered that the graphene oxide – nanomaterial consisting of a carbon fiber atomic cap position positioned in a hexagonal shape – could be the most efficient material to try new pharmaceuticals or to disrupt construction of cellular cell replacement by Parkinson’s disease.
The dopaminergic neurons, which produce the dopamine neurotransmitter, participate in biological processes such as motion, because progressive degeneration and death are caused by Párkinson’s disease, a strain that affects the nervous system and provokes a rigid failure.
Although it is clear that the origin of this pathology is unknown, there are therapies to treat its effects and increase the quality of life of patients. In this form, it is described in previous studies that graphene promotes the differentiation of these dopaminergic cells and prevents them from losing, the new objective of the UMA investigation team is “the search for a cellular tool that allows you to grow and protect in order to improve sorevivir without generating tumor processes or aberrations “.
There is no indication that Noela Rodríguez Losada, the studio’s principal scientist, added that the work is evidence that this material “is the idon for generating cellular support, allowing the adequacy of dopaminergic neurons and favoring the production in addition to the production.” DERIVADOS DEL GRAFENO
The UMA investigator ensures that graphene is a potential material for generating neuroprosthesis through its qualities: it is highly conductive, flexible, biocompatible with cells, capable of obtaining and escalating to industrial level. Thus, for this search, three subtypes of this nanomaterial are generated: the oxidized graphene (GO), the partially reduced graphene (PRGO) and the totally reduced graphene (FRGO).
Then, the scientists from the Department of Human Physiology at the University of Malaga will analyze the powder used to generate the subtypes of graphene as the particles of this material. His intention was to study and exert some toxic effect on the cells, as well as his idiosyncrasies to be used as a neuroprosthesis.
“The results show that the different subtypes of oxidized graphene present a high biocompatibility with dopaminergic cells. In particular, we will see that the PRGO particles favor the assessment of estates and the protection that Rodríguez.
The study, published in the journal Frontiers in Neuroscience, was a collaboration with the UMA’s Central Support Services (SCAI) Support Services; of the Department of Biochemistry of the UMA; of Miguel Ángel Arráez, Director of the Unit of Neurosurgery of the Regional University Hospital of Málaga; de Ernest Arenas, director of the laboratory Biomedicum del Instituto Karolinska (Suecia); Pedro González Alegre, Professor of Neurology at the University of Pennsylvania; of the Department of Mechanical Engineering of the University of Salamanca; and from the company Norway Abalonyx SL, producer of graphene.